These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 25159886)
1. Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and armodafinil in healthy adult males undergoing acute sleep loss. Gasior M; Freeman J; Zammit G; Donnelly P; Gao J; Ferreira-Cornwell MC; Roth T J Clin Psychopharmacol; 2014 Dec; 34(6):690-6. PubMed ID: 25159886 [TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Dinges DF; Arora S; Darwish M; Niebler GE Curr Med Res Opin; 2006 Jan; 22(1):159-67. PubMed ID: 16393442 [TBL] [Abstract][Full Text] [Related]
3. A generalized estimating equation approach to analysis of maintenance of wakefulness testing in a study of lisdexamfetamine dimesylate, armodafinil, and placebo in sleep-deprived adults. Roth T; Freeman J; Zammit G; Donnelly P; Gao J; Ferreira-Cornwell MC; Gasior M J Clin Psychopharmacol; 2014 Oct; 34(5):642-4. PubMed ID: 25180798 [TBL] [Abstract][Full Text] [Related]
4. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Hirshkowitz M; Black JE; Wesnes K; Niebler G; Arora S; Roth T Respir Med; 2007 Mar; 101(3):616-27. PubMed ID: 16908126 [TBL] [Abstract][Full Text] [Related]
5. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study. Herring WJ; Liu K; Hutzelmann J; Snavely D; Snyder E; Ceesay P; Lines C; Michelson D; Roth T Sleep Med; 2013 Oct; 14(10):955-63. PubMed ID: 23920422 [TBL] [Abstract][Full Text] [Related]
6. The effects of armodafinil on objective sleepiness and performance in a shift work disorder sample unselected for objective sleepiness. Howard R; Roth T; Drake CL J Clin Psychopharmacol; 2014 Jun; 34(3):369-73. PubMed ID: 24717254 [TBL] [Abstract][Full Text] [Related]
7. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Roth T; White D; Schmidt-Nowara W; Wesnes KA; Niebler G; Arora S; Black J Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091 [TBL] [Abstract][Full Text] [Related]
8. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. Krystal AD; Harsh JR; Yang R; Rippon GA; Lankford DA J Clin Psychiatry; 2010 Jan; 71(1):32-40. PubMed ID: 20051221 [TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497 [TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Harsh JR; Hayduk R; Rosenberg R; Wesnes KA; Walsh JK; Arora S; Niebler GE; Roth T Curr Med Res Opin; 2006 Apr; 22(4):761-74. PubMed ID: 16684437 [TBL] [Abstract][Full Text] [Related]
11. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921 [TBL] [Abstract][Full Text] [Related]
12. The impact of shift duration on the efficacy and tolerability of armodafinil in patients with excessive sleepiness associated with shift work disorder. Harsh J; Yang R; Hull SG Curr Med Res Opin; 2014 May; 30(5):945-51. PubMed ID: 24450538 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. Calabrese JR; Frye MA; Yang R; Ketter TA; J Clin Psychiatry; 2014 Oct; 75(10):1054-61. PubMed ID: 25099397 [TBL] [Abstract][Full Text] [Related]
14. Armodafinil for the treatment of excessive sleepiness associated with mild or moderate closed traumatic brain injury: a 12-week, randomized, double-blind study followed by a 12-month open-label extension. Menn SJ; Yang R; Lankford A J Clin Sleep Med; 2014 Nov; 10(11):1181-91. PubMed ID: 25325609 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological interventions for sleepiness and sleep disturbances caused by shift work. Liira J; Verbeek JH; Costa G; Driscoll TR; Sallinen M; Isotalo LK; Ruotsalainen JH Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009776. PubMed ID: 25113164 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179 [TBL] [Abstract][Full Text] [Related]
18. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. Brams M; Giblin J; Gasior M; Gao J; Wigal T Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420 [TBL] [Abstract][Full Text] [Related]
19. Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. Killgore WD; Rupp TL; Grugle NL; Reichardt RM; Lipizzi EL; Balkin TJ J Sleep Res; 2008 Sep; 17(3):309-21. PubMed ID: 18522689 [TBL] [Abstract][Full Text] [Related]
20. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. Ermer JC; Dennis K; Haffey MB; Doll WJ; Sandefer EP; Buckwalter M; Page RC; Diehl B; Martin PT Clin Drug Investig; 2011; 31(6):357-70. PubMed ID: 21539403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]